Evidence map›Paper›PMID 37336885›Full record

ArticleNature communications2023

ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion.

Demis Menolfi, Brian J Lee, Hanwen Zhang, Wenxia Jiang, Nicole E Bowen, Yunyue Wang, Junfei Zhao, Antony Holmes, Steven Gershik, Raul Rabadan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Demis MenolfiInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.ORCID 0000-0002-3824-9931
Brian J LeeInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.ORCID 0000-0001-5550-1468
Hanwen ZhangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.
Wenxia JiangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.ORCID 0000-0002-5097-0975
Nicole E BowenDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.ORCID 0000-0003-4269-2167
Yunyue WangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.
Junfei ZhaoProgram for Mathematical Genomics, Department of Systems Biology, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.
Antony HolmesInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.ORCID 0000-0001-7559-2678
Steven GershikInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.
Raul RabadanProgram for Mathematical Genomics, Department of Systems Biology, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA.ORCID 0000-0001-7946-9255
Baek KimDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.ORCID 0000-0001-7986-4335
Shan ZhaInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY, 10032, USA. sz2296@cumc.columbia.edu.ORCID 0000-0002-6568-1818
Cancer Genetics (United States) · USColumbia University · USEmory University · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
The Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2014 to 2024
$17.6M
The role of ATM in the suppression of lymphoid malignancyR01CA158073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2011 to 2026
$5.7M
Towards a quantitative understanding of tumor evolutionR35CA253126 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Raul Rabadan · 2021 to 2026
$5.6M
Lentivirus Replication Strategy and PathogenesisR01AI136581 · NIAID · EMORY UNIVERSITY · PI Baek Kim · 2018 to 2026
$3.9M
The non-catalytic function of PARP2 in DNA repair and cancer therapyR01CA271595 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.9M
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)R01CA254403 · NCI · EMORY UNIVERSITY · PI KIM, BAEK, YU, DAVID SUNG-WEN · 2020 to 2024
$2.9M
SAMHD1 mediated dNTP regulation and HIV in myeloid cellsR01AI162633 · NIAID · EMORY UNIVERSITY · PI Baek Kim · 2021 to 2026
$2.7M
The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppressionR01CA275184 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.7M
The structural function of ATR in development, oncogenesis and cancer therapyR01CA215067 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2017 to 2021
$1.9M
The catalytic and non-catalytic functions of PARP1 in cancer biologyR01CA226852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2018 to 2022
$1.8M
Defining a common mechanism of SAMHD1 function in cancer, HIV, and AGSF31AI157884 · NIAID · EMORY UNIVERSITY · PI BOWEN, NICOLE EILEEN · 2021 to 2022
$86k
NCI NIH HHS P01 CA174653NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA158073NCI NIH HHS R01 CA215067NCI NIH HHS R01 CA226852NCI NIH HHS R01 CA254403NCI NIH HHS R01 CA271595NCI NIH HHS R01 CA275184NCI NIH HHS R35 CA253126NIAID NIH HHS F31 AI157884NIAID NIH HHS R01 AI136581NIAID NIH HHS R01 AI162633
6 · The paper itself

Abstract

The ATR kinase, which coordinates cellular responses to DNA replication stress, is also essential for the proliferation of normal unstressed cells. Although its role in the replication stress response is well defined, the mechanisms by which ATR supports normal cell proliferation remain elusive. Here, we show that ATR is dispensable for the viability of G0-arrested naïve B cells. However, upon cytokine-induced proliferation, Atr-deficient B cells initiate DNA replication efficiently, but by mid-S phase they display dNTP depletion, fork stalling, and replication failure. Nonetheless, productive DNA replication and dNTP levels can be restored in Atr-deficient cells by suppressing origin firing, such as partial inhibition of CDC7 and CDK1 kinase activities. Together, these findings indicate that ATR supports the proliferation of normal unstressed cells by tempering the pace of origin firing during the early S phase to avoid exhaustion of dNTPs and importantly also other replication factors.

Indexed as

DNA ReplicationProtein Serine-Threonine KinasesAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell ProliferationDNA DamageS PhaseAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsProtein Serine-Threonine Kinases

Identifiers

PMID37336885
PMCPMC10279696
OpenAlexW4381251698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.